Completed PHASE2 INTERVENTIONAL NCT00272207

A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia

A Randomized Double-blinded Placebo Controlled Trial Assessing the Effect of the Oral Cannabinoid Nabilone on Pain and Quality of Life in Patients With Fibromyalgia

Sponsor: Valeant Canada Limited

Conditions Fibromyalgia

Interventions Nabilone

Updated 6 times since 2017 Last updated: Aug 24, 2011 Started: Apr 30, 2006 Primary completion: Feb 28, 2007 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00272207, this PHASE2 trial focuses on Fibromyalgia and remains completed. Sponsored by Valeant Canada Limited, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Valeant Canada Limited
Winnipeg Regional Health Authority

Data source: Winnipeg Regional Health Authority

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Winnipeg, Canada